Journal article
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
- Abstract:
-
Objectives We investigated determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike IgG responses in healthcare workers (HCWs) following one or two doses of Pfizer–BioNTech or Oxford–AstraZeneca vaccines.
Methods HCWs participating in regular SARS-CoV-2 PCR and antibody testing were invited for serological testing prior to first and second vaccination, and 4 weeks post-vaccination if receiving a 12-week dosing interva...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Supplementary materials, 343.0KB)
-
(Version of record, 670.8KB)
-
- Publisher copy:
- 10.1016/j.cmi.2021.05.041
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Clinical Microbiology and Infection Journal website
- Volume:
- 27
- Issue:
- 10
- Pages:
- 1516.e7-1516.e14
- Publication date:
- 2021-06-07
- Acceptance date:
- 2021-05-25
- DOI:
- EISSN:
-
1469-0691
- ISSN:
-
1198-743X
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1179027
- Local pid:
- pubs:1179027
- Deposit date:
- 2021-05-27
Terms of use
- Copyright holder:
- Eyre et al.
- Copyright date:
- 2021
- Rights statement:
- © 2021 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record